Found Health Review: The $49 Plan Needs 12 Months and Insurance

The one-sentence version

Found Health has the strongest named clinical bench of anything we grade — a former medical director of the American Board of Obesity Medicine, a Columbia endocrinologist, a Stanford psychiatrist-obesity physician — and it states its compounding standard in its own words on its own product pages, which most of this board will not do. It is also, entirely and only, a weight-loss membership: fourteen medications, every one of them for weight loss, and nothing for cognition, energy, longevity or the microbiome. Its advertised "$49/mo" needs both a twelve-month commitment and commercial insurance, and its binding Offer Terms disagree with its own pricing page on three of four cells. It grades C, 6 points out of 14, computed from published terms alone and blind to who pays us. Found is a paid partner here.

What it is, and what it is not

Found Health, Inc. sells a membership: a licensed clinician reviews an online health assessment, prescribes if appropriate, and your plan covers the care around that. Fourteen medications sit behind it:

• •Injectable GLP-1: compounded semaglutide, compounded tirzepatide, compounded liraglutide, plus brand Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza and Trulicity
• •Oral GLP-1: Foundayo™ (orforglipron) and Rybelsus
• •Oral non-GLP-1: Contrave®, metformin, topiramate and zonisamide

That is the entire list. No NAD+. No sermorelin or any other peptide. No glutathione, no B-12 injection, no methylene blue, no testosterone or hormone replacement, no BPC-157 or TB-500, no supplements, no diagnostics. The only adjacent assets are free calculators and blog posts.

We are saying that plainly because Found is often filed as a longevity-adjacent operator on the strength of metformin appearing on its list. Metformin is on the list — as a weight-loss generic, in a plan Found calls its Generics plan, not as a geroprotector. If metformin is what you are after, what its longevity evidence actually shows is a more useful place to start than a menu.

What it really costs

The $49 is a corner cell. Found's public pricing page never mentions $49. The real table lives inside the binding Offer Terms, published as an image rather than as text, and $49 is the bottom-right of it: twelve months of commitment and commercial insurance. Without insurance the twelve-month rate is $99. Without the commitment, insured, it is $89. The standing month-to-month cash rate is $149.

Two traps live in that same table. Billing is every 4 weeks, which is 13 cycles a year, not 12 — so a "$89/mo" plan bills $1,157 a year, not $1,068. And Found defines its "12 month" term as 48 weeks, which is about eleven calendar months of coverage for a twelve-month commitment.

And the binding document does not agree with the marketing page. On the compounded GLP-1 plan, /plans-and-pricing advertises $99/$169 on twelve months and $199/$289 monthly, while the Offer Terms — the document you are actually agreeing to — say $149/$199 and $199/$299. Three of those four cells disagree. Only one of the two documents is the contract.

Why that zeroes the price factor. Our rubric asks for one all-in figure, visible before you commit, that a buyer with no commitment actually pays. The failure here is not the $49 headline; plenty of rows survive a headline that turns out to be a prepay, and Found's own $89 and $149 are perfectly clear once you find the table. The failure is that two documents published by the same company on the same day quote different prices for the same plan, and the one a shopper reads is not the one that binds. Compare Gala Health, which loses the same four points for advertising a yearly rate as a monthly one — Found's version is subtler and, if anything, harder for a reader to detect.

Brand-name prices, for scale: Ozempic about $1,100 a month, Mounjaro about $1,100, Wegovy from $650, Zepbound from $650, Foundayo about $149.

What Found does better than almost anything here

The clinical bench. Found names, with credentials: Dr. Rekha Kumar, MD MS (Senior Medical Advisor, former medical director of the American Board of Obesity Medicine), Dr. Jonathan Larson, MD MBA (Medical Director), Dr. Judith Korner, MD PhD (Columbia), Dr. Shebani Sethi, MD (Stanford) and Dr. Kyu Rhee, MD MPP. It also discloses, in its own words, that Dr. Kumar does not interact directly with Found patients — a caveat most companies would leave you to discover. Naming a bench like that and then volunteering its limit is the kind of disclosure this board exists to reward.

The compounding standard, stated properly. On its compounded-medication product pages Found writes: "Found partners exclusively with 503A-licensed pharmacies — meaning every medication dispensed through Found is compounded by a licensed pharmacist pursuant to your specific prescription, in a facility that must comply with USP standards for sterile preparation." That is a claim about who fills your prescription, not a general explanation of the statute, which is the distinction our methodology turns on — so Found takes the full two pharmacy points. What it does not do is name the facility.

Care is inside the plan price. "Every plan includes full access to our licensed medical team, personalized care plans," covering "medical, lifestyle, and behavioral guidance from licensed clinicians" plus a member community. That is a statement about what the money buys, and it earns both the oversight and the support points.

Insurance is real. Found accepts insurance across 41 states, which almost nothing else on this board does — and for a category that is overwhelmingly cash-pay, that is a material difference to what people actually pay.

The state list, and the two places it argues with itself

Found publishes a 41-state selector for the insurance plans it accepts. On that same page, two contradictions:

• •New Mexico renders an "available plans" panel while being absent from the 41-state selector.
• •California is in the accepted list, yet its own panel reads "No plans available for this state."

Neither is fatal. Both mean the answer you get depends on which control you touched, so confirm your own state before assuming coverage.

Cancellation is the other thing to price in: the membership is refundable only within three days or before your first consult; medications and lab kits are non-refundable once shipped; renewals are non-refundable; and cancelling needs 48 hours' notice before the next renewal — which, on a four-week cycle, comes round thirteen times a year.

The evidence, and why it matters that this is GLP-1 and nothing else

Here is the part that cuts in Found's favour, and it is worth stating as clearly as the criticism.

GLP-1 receptor agonists are the only category this site covers with hard outcome data. Semaglutide produced about 15% mean weight loss in the STEP 1 trial² and tirzepatide up to about 21% in SURMOUNT-1³; the SELECT trial then showed a 20% reduction in major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity but without diabetes⁴. Nothing on the compounded longevity shelf — NAD+, sermorelin, glutathione — has anything of that quality behind it; the 2026 systematic review of NAD+ for anti-aging concluded clinical effectiveness "remains inconclusive"⁵.

So a reader deciding between Found and a compounded NAD+ programme is not choosing between longevity and not-longevity. They are choosing between a drug class with cardiovascular-outcome trials and a category without them. What Found cannot do is answer the question this board is usually asked, because it sells nothing else.

Two caveats belong beside that. Found's compounded semaglutide, tirzepatide and liraglutide are not FDA-approved — FDA's position is that compounded drugs are not FDA-approved and it does not verify their safety, effectiveness or quality before marketing¹ — and lean-mass loss on GLP-1 therapy is a real clinical concern that the guidance is still catching up with⁶. Our GLP-1 explainer goes through both.

Who should use it, and who should not

Use it if weight loss is the goal, insurance is a factor, and you want a named clinical bench and a stated compounding standard behind the prescription. On those terms Found is one of the better-run operators in the category, and the 41-state insurance path is genuinely differentiated.

Skip it if you came here for NAD+, peptides or hormones — it sells none of them and will not start. Skip the $49 arithmetic unless you have commercial insurance and are prepared to commit for a year that is really 48 weeks. And before you sign anything, read the Offer Terms rather than the pricing page, because they are the document that binds and they say different numbers.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Found takes two for clinical oversight, because clinician access is stated as inside the plan; two for pharmacy, because it publishes a 503A claim about who fills your prescription on a surface it controls; and two for human support, on published ongoing guidance from licensed clinicians. It takes zero for price transparency, because its binding terms and its pricing page quote different figures for the same plan, and zero for its longevity line, because it has none. Six out of fourteen: a C.

Notice what that is, and what it is not. Found is clean on three of five axes and drops the other two for different reasons — one fixable in an afternoon by reconciling two documents, one structural and permanent unless the company changes what it sells. A provider with no longevity line cannot reach our A band whatever else it does, because the most it can score is ten and the A floor is eleven. That cap is the whole point of the factor: a well-run weight-loss membership should not be able to out-grade a longevity clinic on a page a reader opened to find longevity clinics. If the membership question itself is what you are weighing, concierge versus membership pricing is the better read. The full graded field is at our provider rankings.